Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

Isomorphic Labs raises $5 billion for AI drug development

Published 18 November 2026 · All stories from this day

Isomorphic Labs has raised $5 billion in a Series C round to expand its artificial intelligence drug-design work and advance its treatment programs toward clinical trials, the company announced November 17. The financing was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and all existing investors also participating. Isomorphic said the round was oversubscribed, but did not disclose its valuation or the amount contributed by each investor.

The company said proceeds will support development of its drug-design engine, IsoDDE, research into additional areas of biology, its therapeutic pipeline and infrastructure for clinical development. It is seeking to move its first programs from preclinical research into human testing, though the announcement gave no updated timetable for starting trials.

Isomorphic reported positive preclinical results in its internal oncology and immunology programs, as well as in work with partners. The company did not identify the drug candidates or release detailed data supporting those results. The findings are therefore company-reported preclinical outcomes, not evidence that its medicines are safe or effective in people.

Now playing
0:00 / 0:00